As of May 01
| +0.05 / +0.55%|
The 3 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 13.00, with a high estimate of 15.75 and a low estimate of 13.00. The median estimate represents a +41.00% increase from the last price of 9.22.
The current consensus among 3 polled investment analysts is to Buy stock in Cancer Genetics Inc. This rating has held steady since April, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.